Allergology international : official journal of the Japanese Society of AllergologyHumansDermatitisAtopicAntibodiesMonoclonal
Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study.
Yoko Kataoka, Motohiro Ebisawa, Akio Tanaka, Mizuho Nagao, Elizabeth Laws, Hisakatsu Nawata, Kazuhiko Arima, Daisuke Watanabe, Xin Lu, Jennifer Maloney, Ariane Dubost-Brama, Ashish Bansal, Kenji Yahata
Published: 202610.1016/j.alit.2025.09.002
Abstract
BACKGROUND: Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label exten…
Preview only. Read the full abstract at the source